Obesity, a disease increasing cardiometabolic risks and mortality, often accompanies metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD is characterized by fat accumulation in the liver without other secondary causes. This study explores clinical outcomes in obese patients without DM co-diagnosed with MASLD. Conducted as an observational study, it utilized data from the National Inpatient Sample from 2017 to 2020 focusing on obese adults over 18 years, with a BMI >30 kg/m^2, and MASLD diagnosis, excluding those under 18 or with DM. Multivariable logistic and Poisson regression analyses determined the clinical outcomes, considering a p-value <0.05 significant. Among 1,140,000 obese adults without DM, 23.4% had MASLD, predominantly white males aged 53-57. The study compared MASLD and non-MASLD groups, revealing higher rates in % in the MASLD group for conditions like anemia (21.8 vs 13.5), pulm HTN (7.6 vs 4), HF (26.6 vs 15.9), Afib (18.7 vs 13.7), PVD (2.4 vs 2.2), ACS (7 vs 4.2), STEMI (1.1 vs 0.6), COPD (19 vs 14.6), CKD (19.5 vs 11), PE (7.2 vs 5.2) and incidences of nicotine (19 vs 15.8) and alcohol use (16 vs 4.3). The former group also had worse primary and secondary outcomes as detailed in Table 1. The findings underscore the importance of obesity detection and management in such populations for better clinical outcomes and prognosis.
S. Kishore: None. L. Khokhlov: None. F.R. Mateo: None. P. Rajbhandari: None. T. Ikpeze: None. M. Kishore: None. G.E. Ajenaghughrure: None. A. Thapa: None.
